TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00566319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREPARE with pedometer
Description: Structured educational programme with pedometer use

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PREPARE
Description: Structured educational programme
Study: NCT03086811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother Infant Feeding Interaction very early training
Description: weekly training meetings on 4 topics:~1. What - proper nutrition and supplements for solid feeding phase (dietitian); What - the meaning of feeding to mother and infant (social worker).~2. Who - feeding skills - knowledge and actual practices~3. From anxiety to serenity - knowledge concerning growth patterns and common physical and emotional issues troubling parents of infants 4-12 months old.~4. Prevention of obesity and emotional eating - practical advise and tips.
Study: NCT04106492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ3370
Description: SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin
Study: NCT02826330

Intervention type: OTHER
Intervention: biomarkers
Description: fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms
Study: NCT04106492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ3370
Description: SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ3370
Description: SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ3370
Description: SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ3370
Description: SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ3370
Description: SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin
Study: NCT03957928

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat cookie
Description: to determine the effects of low fat cookie consumption on satiety and metabolic parameters in overweight/obese adults

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango fruit
Description: to determine the effects of fresh mango pulp consumption on satiety and metabolic parameters in overweight/obese adults
Study: NCT01322620

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given. Participants are to complete a questionnarie in the study.
Study: NCT02177032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine
Description: 12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccines + Rabies immunoglobulins
Description: 12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies vaccine
Description: 8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies vaccines + Rabies immunoglobulins
Description: 8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle.
Study: NCT01054989

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fat/Inflammation effects
Description: Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fat/Inflammation effects
Description: Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fat/Inflammation effects
Description: Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fat/Inflammation effects
Description: Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
Study: NCT01770418

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation with Concurrent Chemotherapy
Description: RADIATION: Proton Radiotherapy~Dose Level 1: 60 Gy (RBE) at 2.5 Gy(RBE) per fraction x 24 fractions~Dose Level 2: 60 Gy (RBE) at 3 Gy (RBE) per fraction x 20 fractions~Dose Level 3: 60.01 Gy (RBE) at 3.53 Gy (RBE) per fraction x 17 fractions~Dose Level 4: 60 Gy (RBE) at 4 Gy (RBE) per fraction x 15 fractions~CONCURRENT CHEMOTHERAPY:~Paclitaxel at a dose of 45 mg/m2 and Carboplatin at a dose of AUC 2 mg/min/ml (a total of 3-5 weekly doses) OR Cisplatin 50mg/m2 days 1, 8, 29, and 36 and Etoposide 50mg/m2 days 1-5, 29-33. For non squamous histology, Carboplatin AUC 5 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days OR Cisplatin 75 mg/m2 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days.~Adjuvant chemotherapy is optional.
Study: NCT02835248

Intervention type: OTHER
Intervention: Fall Detection
Description: All participants will wear a device configured to detect falls.
Study: NCT01109472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient magazine
Description: patient magazine individually tailored to patient's prior feedback
Study: NCT04592887

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FLASH Radiotherapy
Description: FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.
Study: NCT00494793

Intervention type: PROCEDURE
Group type: OTHER
Intervention: VAWC and mesh mediated fascial traction
Description: The first period of 2-5 days only the abdominal VAWC dressing is applied. On day 3-10 a polypropylene mesh is sutured to the fascial edges, between the two layers of the VAWC system, and tightened.~The VAWC dressing is changed and the mesh tightened every 2-3 days, resulting in gradual approximation of the fascial edges.~Finally the mesh is removed and the fascia is closed
Study: NCT00897234

Intervention type: OTHER
Intervention: Mass Spectrometry
Description: Levels of Cathepsin D (CD) and fatty acid synthase (FAS) will be measured using isobaric tag labeling coupled with mass spectrometry. RNA concentration will be measured using spectrophometer and purity will be analyzed.
Study: NCT02826330

Intervention type: OTHER
Intervention: biomarkers
Description: fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms

Intervention type: OTHER
Intervention: biomarkers
Description: fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms
Study: NCT04130529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adjusted group CBT-i for Bipolar disorder
Description: CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. In addition components targeting circadian rhythm problems and problems with very high or very low levels of activity are included.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep lectures
Description: Lectures on the topic of sleep.
Study: NCT03345134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475 and BCG
Description: combination treatment with MK-3475 and BCG after endoscopic ablation
Study: NCT04950088

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand-held video game device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand-held video game device
Study: NCT02204176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise info
Description: Discussion:~* benefits of exercise~* types of exercise~* exercise guidelines~* components of an exercise session~* how to reduce risk of injuries

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise info
Description: Discussion:~* benefits of exercise~* types of exercise~* exercise guidelines~* components of an exercise session~* how to reduce risk of injuries

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise info
Description: Discussion:~* benefits of exercise~* types of exercise~* exercise guidelines~* components of an exercise session~* how to reduce risk of injuries

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Description: Discussion of:~* barriers to exercise and how to address/overcome barriers~* how to create detailed exercise plans

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Description: Discussion of:~* barriers to exercise and how to address/overcome barriers~* how to create detailed exercise plans

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Industriousness
Description: Discussion of:~* realistic monitoring of efforts related to exercise~* reaching and pushing past thresholds for sustained effort for exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pedometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pedometer

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: pedometer
Study: NCT01716117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surpass Flow Diverter
Description: Treatment of an intracranial aneurysm involves the placement of a specially designed metallic mesh tube in a vessel in the brain where an aneurysm is located. The device looks like a fishnet sock with both ends open. Each device is delivered through a small catheter (a long, flexible tube). The catheter containing the device is inserted and advanced into a vessel in the brain. The device is then placed in the brain vessel by releasing it from the catheter. Once the device is placed inside the brain vessel, it is intended to reinforce the area of the vessel that is weakened and bulging (the aneurysm), and to cause blood to flow down the vessel and away from the aneurysm while allowing blood in the aneurysm to clot. This procedure is called an endovascular aneurysm treatment because the device is delivered through the blood vessels.
Study: NCT03702556

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI scan
Description: 7.0 tesla functional MRI scan

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI scan
Description: 7.0 tesla functional MRI scan

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI scan
Description: 7.0 tesla functional MRI scan
Study: NCT01950026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy application
Description: * Height, weight and BMI verification~* subjects in supine position after 20 minutes of resting~* cryotherapy application by cold thermal bag (thermoGel brand) size P~* 15-20 cm above the ASIS~* temperature verified before and after cryotherapy application with an infrared thermometer CA 380 CASON brand, Brazil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy application
Description: * Height, weight and BMI verification~* subjects in supine position after 20 minutes of resting~* cryotherapy application by cold thermal bag (thermoGel brand) size P~* 15-20 cm above the ASIS~* temperature verified before and after cryotherapy application with an infrared thermometer CA 380 CASON brand, Brazil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy application
Description: * Height, weight and BMI verification~* subjects in supine position after 20 minutes of resting~* cryotherapy application by cold thermal bag (thermoGel brand) size P~* 15-20 cm above the ASIS~* temperature verified before and after cryotherapy application with an infrared thermometer CA 380 CASON brand, Brazil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy application
Description: * Height, weight and BMI verification~* subjects in supine position after 20 minutes of resting~* cryotherapy application by cold thermal bag (thermoGel brand) size P~* 15-20 cm above the ASIS~* temperature verified before and after cryotherapy application with an infrared thermometer CA 380 CASON brand, Brazil
Study: NCT00321113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroids
Description: oral
Study: NCT03867058

Intervention type: BEHAVIORAL
Intervention: Electrode selection/electrode configuration
Description: Electrodes will be chosen based on their spatial tuning curves. Focused stimulation will be applied to electrodes with good temporal processing acuity.
Study: NCT04187053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional mechanical therapy
Description: Both experimental and sham arms will receive the Conventional mechanical therapy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conventional mechanical therapy
Description: Both experimental and sham arms will receive the Conventional mechanical therapy

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Sham group will receive saline as a sham for methylene blue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Experimental arm will receive methylene blue

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light emitting laser
Description: Experimental arm will receive Light emitting laser

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-light emitting laser
Description: Sham group will receive Non-light emitting laser
Study: NCT03642951

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Treatment
Description: The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A\&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A\&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
Study: NCT03068663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling
Description: Patients will receive their standard treatments, surgery with/without chemotherapy. A patient intervention consists in taking samples of blood, saliva, faeces, lung/tumour tissue, and bronchoalveolar lavage fluid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling
Description: Patients will receive their standard treatments, surgery with/without chemotherapy. A patient intervention consists in taking samples of blood, saliva, faeces, lung/tumour tissue, and bronchoalveolar lavage fluid.
Study: NCT00517907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preimplantation factor (PIF-1)
Description: The study will include 6 patients and will last for at least six months. The first three patients will receive PIF-1 (0.5 mg/kg/day for 14 days) by subcutaneous injection. The dosage in the next three patients may be increased to 1 mg/kg/day for 14 days.~Patients will be treated serially: each patient will be followed for 2 weeks after cessation of PIF-1 administration before the next patient begins PIF-1 administration.
Study: NCT01200420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miravirsen
Description: SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: SC injection
Study: NCT02454179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Study: NCT01016977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
Description: Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
Description: clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
Study: NCT02773875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial pancreas system (Algorithm + CGM + pump)
Description: The AP system using fault detection algorithms will determine whether insulin infusion problems are occurring and may prevent severe hyperglycemia due to its predictive nature
Study: NCT03939455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Augmented Screening tool
Description: Tablet-based intervention
Study: NCT00712309

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lifestent
Description: Stent for endovascular treatment of popliteal artery lesions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon-angioplasty (PTA)
Description: PTA for endovascular treatment of popliteal artery lesions
Study: NCT01816854

Intervention type: DEVICE
Intervention: Stenting
Study: NCT03490526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Root canal disinfection with XP-endo Finisher
Description: The XP-Endo® finisher will be used next to the X-Smart Plus endodontic motor, with speed settings at 800rpm and torque at 1 N.cm. Irrigation with 17% EDTA and 2.5% NaOCl will be performed in three cycles of one minute each. In each cycle the XP-Endo will be used in the working length in continuous and slow movements of entrance and exit, with amplitude of 5mm, for a period of 1 minute, followed by new irrigation with 2.5ml of EDTA solution or hypochlorite of sodium 2,5%. Finally, the channel will be completely dry with absorbent paper tips

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal disinfection with passive ultrasonic irrigation
Description: For cleaning using passive ultrasonic irrigation, the E1 Irrisonic tip (Helse Ultrasonic, Ribeirão Preto, SP), will be used with Jetlaxis Sonic BP LED (Schuster, Santa Maria, RS). The insert has a diameter equivalent to a manual file 20, with reduced taper (0.01). The power used will be 10%. With root canals flooded with 17% EDTA, the irrigation tips will be coupled to the ultrasound and 1mm shorter than the working length. These tips will be kept in the center of the canal avoiding contact with the dentin walls. The irrigation will be performed in three cycles, and in each cycle the irrigation tips will be activated for 1 minute followed by new irrigation with 2.5ml EDTA. The same procedure will be repeated with 2.5% NaoCl. Finally, the channel will be completely dry with absorbent paper tips.
Study: NCT00988195

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Recombinant Human Arginase I
Description: Week 1 (Single Dose); Weeks 3 - 11 (Weekly Dose x 8 weeks)in 8 escalation doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Weeks 13-24 (once every 3 weeks)
Study: NCT00473941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: Behavioral intervention using writing about cancer to improve quality of life outcomes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expressive writing
Description: Behavioral intervention using writing about cancer to improve quality of life outcomes
Study: NCT04436939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant
Description: Following dental implant installation, PEEK or Ti healing abutments were placed according to the split mouth study design.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant
Description: Following dental implant installation, PEEK or Ti healing abutments were placed according to the split mouth study design.